Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Opens Tokyo Office, Strengthens Japanese Presence

This article was originally published in PharmAsia News

Executive Summary

British specialty drug maker Shire Feb. 23 opened a representative office in Tokyo. The company appointed former Genzyme Japan executive Soh Fujiwara as managing director. Shire's Hunter syndrome drug Elaprase (idursulfase) is marketed currently in Japan through collaboration with Genzyme. With the opening of the Tokyo office, the company aims to introduce specialty drugs to treat inflammatorily bowel disease, hyperphosphatemia and Fabry's disease to Japan. The Tokyo office is Shire's third office in the Asia-Pacific region, after Singapore and Australia. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts